KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Vertex Pharmaceuticals' Income from Continuing Operations rose 3046.0% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 billion, marking a year-over-year increase of 83808.81%. This contributed to the annual value of $4.0 billion for FY2025, which is 83808.81% up from last year.
  • Vertex Pharmaceuticals' Income from Continuing Operations amounted to $1.2 billion in Q4 2025, which was up 3046.0% from $1.1 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Income from Continuing Operations high stood at $1.2 billion for Q4 2025, and its period low was -$3.6 billion during Q2 2024.
  • Its 5-year average for Income from Continuing Operations is $635.1 million, with a median of $882.4 million in 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Income from Continuing Operations surged by 110970.15% in 2022 and then plummeted by 49244.29% in 2024.
  • Vertex Pharmaceuticals' Income from Continuing Operations (Quarter) stood at $770.1 million in 2021, then rose by 6.34% to $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then fell by 5.76% to $913.0 million in 2024, then soared by 30.46% to $1.2 billion in 2025.
  • Its Income from Continuing Operations was $1.2 billion in Q4 2025, compared to $1.1 billion in Q3 2025 and $1.0 billion in Q2 2025.